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ABSTRACT
The expression of genes which may be involved in the regulation of
human mammary epithelial cell growth [transforming growth factors a
and /Â¡]and tumorigenesis |r-mÂ»r,erbE2, epidermal growth factor receptor
(EGFR), Ihi-ri/v, pS2\ has been compared in similarly cultured normal
cell strains and tumor cell lines. We have found that the normal breast
cells produce high levels of EGFR mRNA, which are translated into
nearly 10* low affinity epidermal growth factor-binding molecules/cell.
In the estrogen receptor-negative lines examined, the EGFR gene was
expressed at levels comparable to those in the normal cells. In contrast,
EGFR and transforming growth factor a mRNAs were reduced in estro
gen receptor-positive tumor lines compared to estrogen receptor-negative
lines and normal cells. Steady state mRNA levels for transforming growth
factor ft. erbB2, c-myc, and I la-ruv in the normal cells were greater than
or comparable to those in all of the breast tumor lines. Furthermore, in
the absence of gene amplification, only one of the genes examined (i.e.,
pS2) was overexpressed in a subset of the tumor cells compared to their
normal counterparts. Several reports by other investigators have de
scribed overexpression of some of these genes in breast biopsies and in
tumor lines in studies lacking normal controls. Thus, our results, in which
the same genes were not overexpressed compared to normal cells unless
amplified, underscore the importance of including appropriate normal
controls in studies aimed at defining aberrant patterns of gene expression
in tumor cells.
INTRODUCTION
A characteristic property of tumor cells is the unregulated
expression of genes encoding growth factors, their receptors,
and/or various intermediates in the complex network of cellular
growth control. Aberrant gene expression due to amplification
and/or rearrangement of particular protooncogenes has been
associated with specific forms of cancer (1, 2).
With the availability of cloned genes to use as hybridization
probes, it has become possible to analyze the expression and
structure of particular genes by comparing tumor cells with
their normal counterparts. We have taken this approach in
initiating a study of human breast cancer. A unique feature of
this analysis is the use of normal mammary epithelial cells
grown in long-term cell culture as controls for comparison with
a series of ER+3 and ERâ€”tumor cell lines (3). In previous
studies, established breast carcinoma cell lines have been ex
amined without such a comparison (4-8).
A second feature of this analysis has been the use of a new
medium (9), which supports the growth of both normal and
tumor cells. Previous efforts have been devoted to the devel-
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opment of techniques and media which allow the growth of
normal human mammary epithelial cells in culture (10-14). In
1984, the first serum-free medium for long-term culture of
these cells was developed by Hammond et ai. (15). However,
since most tumor cell lines do not grow in this medium, we
have made modifications which result in long-term growth of
normal human mammary epithelial cells as well as the growth
of tumor cell lines (9). In this medium (DFCI-1), normal breast
epithelial cells from mammoplasties have been grown at popu
lation-doubling times of approximately 20 h for 15-20 passages
before senescence. Unlike the immortal HBL-100 milk epithe
lial cell line frequently used as a normal control (16), these cells
are not transformed. The tumor cell lines examined in this
report were originally established in media with 10% FCS (Ref.
17; see references therein); they grow for several passages but
not indefinitely in DFCI-1 medium. In this paper, we have
compared normal cells grown in DFCI-1 medium with tumor
cell lines grown in either a-MEM plus 10% FCS or DFCI-1
medium.
We have analyzed the expression of a series of genes known
or suspected to be involved in mammary tumorigenesis. The
EGF receptor gene was chosen because several studies have
indicated an inverse relationship between the number of estro
gen receptors and EGFR in breast tumor tissues (18-21). We
have also assessed the expression of the estrogen-responsive
pS2 gene, which encodes a secreted polypeptide of unknown
function (22), since high levels of its mRNA have been detected
in approximately 90% of ER-positive breast tumor specimens,
only rarely in ER-negative biopsies, and never in normal mam
mary tissue (23).
Other genes involved in growth regulation, including erbB2
(24-27), c-myc (26, 28-30), and Ha-ras (31-34), are amplified
and/or overexpressed in different subsets of breast tumor biop
sies and have therefore been included in this study. In addition,
we have examined expression of the genes for TGFo and TGF/3,
two peptide growth factors secreted by and probably involved
in growth control in breast epithelium (6, 35-37).
MATERIALS AND METHODS
Cells and Culture Conditions. The three normal human mammary
epithelial cell strains used in this study were derived from reduction
mammoplasty specimens from different individuals. Strain 30N was
developed in this laboratory following published procedures (38). The
development and characterization of growth requirements for the 172
and 184 strains have been described (14, 39). For our experimental
purposes, the three normal strains were grown in DFCI-1 medium,
containing 1% FCS (9). Breast tumor cell lines T47D. MDA-MB231,
BT-20, and ZR-75-1 [all from ATCC] and MCF-7 (Michigan Cancer
Foundation) and Hs578T [H. Smith (40)] were cultured in a-MEM
supplemented with 2 mM glutamine, 10 Mg/ml insulin, 1 mg/ml dex
trose, 0.1 mM minimal essential amino acids, and 10% FCS unless
otherwise indicated. Penicillin (100 units/ml) and streptomycin (100
Mg/ml) were present in both media. For gene expression studies in
DFCI-1 medium, subconfluent tumor cell cultures growing in a-MEM
+ 10% FCS (above) were seeded (at 2x10' cells/pi50 dish) in DFCI-
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1 medium. Cells were harvested 3 days later at 60-70% confluence and
RNA isolated as described below.
RNA Isolation and Analysis. Cell monolayers approximately 50%
confluent were lysed in 4 M guanidinium isothiocyanate and purified
by centrifugation through a 5.7 M CsCl cushion (41). Total RNA was
denatured and analyzed on a 1.3% agarose-2.2 M formaldehyde gel,
and the RNA was electroblotted to Zetabind nylon filters (Bio-Rad).
Filters were prehybridized for 2 to 4 h at 42'C in l M NaCl, 50%
formamide, 10% dextran sulfate, 1% SDS, and 250 Mg/ml sonicated
salmon sperm DNA. Hybridization with 32P-labeled probes [2 x 10'
dpm/ng DNA (42)] was performed for 24-36 h at 42Â°C;the filters were
washed for 30 min in 2x SSC/0.2% SDS at 25Â°Cand for 1-2 h in
2x SSC-1% SDS at 65Â°C.Dot blot analysis was performed by spotting
2-fold serial dilutions of total RNA (denatured in 3.75% formaldehyde-
4x SSC at 65"C for 15 min) onto Zetaprobe nylon filters using a
Schleicher & Scimeli dot blot manifold. Hybridization conditions were
identical to those for the Northern blot analysis.
DNA Isolation and Southern Blot Analysis. High molecular weight
DNA was isolated from cultured cells (43). Five ^g of DNA were
digested with the restriction enzyme /A/mill, fractionated on 0.7%
agarose gels, and blotted onto nylon filters by the alkaline transfer
procedure (44). Hybridization to 32P-labeled probes was for 12-24 h at
65Â°Cin l M NaCl, 1% SDS, 10% dextran sulfate, and 250 ng/ml
denatured salmon sperm DNA. Filters were washed at 65Â°Cin 2x
SSPE-1% SDS for 30 min and O.Sx SSPE-1% SDS for 30 min-1 h
before autoradiography.
Source of Hybridization Probes. The DNA probes used in the analysis
are as follows: the Â£coRl 1.35-kilobase fragment from pSP6C17N3
(45) is specific for TFGo; the Clal/EcoRl 1.4-kilobase fragment from
pmycB122 (46) corresponds to the 3rd exon of c-myc, the Â£coRI1.8-
kilobase fragment from HER64-1 (47) contains the 5' part of the
EGFR cDNA; the 1.6-kilobase EcoRl internal fragment from the cDNA
(7) recognizes erbB2; the 1-kilobase Â£coRIfragment from p/3AS (48) is
specific for TGF/3; the 600-base pair Smal fragment from pEJ6.6 (49)
recognizes Ha-ros; the 570-base pair EcoRl-Sall fragment from p6al
(50) detects N-ras mRNA; the 400-base pair Pstl A fragment is at the
5' end of the cDNA for pS2 (51); the 2.0-kilobase Pstl fragment from
pAl bearing the chicken cDNA recognizes 0-actin (52).
EGF Receptor Binding and Scatchard Analysis. For EGF binding
experiments, cells were grown to confluence in 35-mm 6-well dishes
(1.0-1.5 x IO6cells/well), then serum and growth factor deprived for
20 h. After 2 washings with F-\2/a-MEM (1:1) salts containing 1%
(w/v) bovine serum albumin, cells were incubated for 2 h at 37Â°Cin 0.5
ml of the same buffer containing 2.5 ng/ml I25I-EGF (Amersham; 170
fiCi/iig) in the presence and absence of IO"7 M unlabeled EGF (Sigma;
receptor grade). Following this incubation, the cells were washed twice
with ice cold 150 mM NaCl and lysed in 0.5 ml 0.2 N NaOH. Radio
activity was determined in a Minaxi gamma counter with a counting
efficiency of 55%. Specific binding is the difference between total
binding and the number of counts bound in the presence of excess
unlabeled EGF. Under these conditions, nonspecific binding is not
greater than 5% of the total. Scatchard analysis was performed under
similar conditions except that increasing amounts of '"Â¡-labeled EGF
(0.05-10 ng/ml) were added to the incubations.
RESULTS
Normal Breast Cells Produce Higher Levels of EGF Receptor
RNA than ER+ Breast Cancer Cell Lines. The expression of
the EGF receptor gene was investigated by quantitating steady
state levels of its RNA by Northern blot analysis of total cellular
RNA. Fig. \A (top) shows the gel electrophoretic profiles of
normal ( 172 and 184, Lanes 1 and 2) and tumor (MCF-7, Lane
3) cell RNAs, hybridized with the indicated probes. The normal
cells synthesize a 10.5-kilobase transcript of the EGF receptor
gene which is not detected in the MCF-7 cells. Hybridization
of the same filter to a chicken 0-actin probe confirms the
presence of equivalent RNA amounts in all lanes (Fig. IA,
bottom).
The analysis of other preparations of MCF-7 RNA using dot
blots (Fig. \B, Lane 4) or Northern hybridization (Table 1)
shows that the MCF-7 as well as the ZR-75-1 (Lane 5) and
T47D (Lane 7) cell lines, contain quantities of EGF receptor
mRNA approximately 16-fold lower than those found in the
three normal strains (Lanes 1-3). By contrast, the ER- MDA-
MB231, Hs578T, and BT-20 cell lines (Fig. IB, Lane 6; Table
1) produced much higher amounts of EGFR mRNA. The
highest levels were found in BT-20 cells (Table 1), in which the
gene is amplified (53, 54).
High EGFR mRNA Expression Is Not Due to Gross Altera
tion or Amplification of the Gene in Normal Cells. To determine
whether high EGFR mRNA expression in the normal cells was
a result of gene amplification, the organization and copy num
ber of the EGF receptor gene in the normal breast cells was
compared with MCF-7, BT-20, and A431 [adenocarcinoma cell
line, where amplification of the EGFR gene was first described
(47)]. No gross genomic rearrangements were observed by
analysis of Â£eoRI,Mspl- [data not shown], or Aa/nHI-restricted
total DNA [Fig. 2] using cDNA probes corresponding to 5' and
3' [data not shown] segments of the mRNA [pHER-A64-l and
A64-2, respectively (47)]. A BamHl restriction fragment length
polymorphism (Â»3.9 kilobases) particular to the 184 normal
strain was, however, noted (Fig. 2). The EGFR gene dosage in
the normal cells is comparable to that detected in the MCF-7
line. The gene is amplified in the BT-20 and A431 lines ap
proximately 7- and 12-fold, respectively, when compared to the
184 strain in DNA dot blot analyses (data not shown), in
agreement with other studies (47, 54). Thus, the elevated
expression of EGFR mRNA in the normal cells is not the result
of a detectable change at the genomic level.
Increase of EGF-binding Capacity of the Normal Cells Relative
to the Tumorigenic MCF-7 Cells. To confirm that the high
levels of mRNA observed in the normal cells were translated
into an active protein, we compared the EGF-binding capacity
of the 184 strain with that of the MCF-7 cells, which express
1-3 x IO3receptors/cell (4, 5). As indicated in the two experi
ments shown in Table 2, EGF binding to normal 184 cells is
20- to 40-fold higher than to MCF-7 cells, irrespective of the
final cell densities. These measurements were performed under
conditions where maximal, saturable binding occurred for both
cell types (i.e., 2 h at 37Â°C)with the EGF concentration
determined by saturation binding studies (Fig. 3).
Scatchard analysis of the EGF binding data for the normal
breast epithelial cells demonstrates the existence of Â»5.8x 10"
EGF receptor molecules/cell with a Ka of 0.96 HM(r2 = 0.97)
(Fig. 3, inset). Thus, the high mRNA expression of the EGFR
gene in the normal mammary epithelial cells translates into a
high level of EGF-binding proteins in these cells. This receptor
number is comparable to those reported for some tumor lines
which lack estrogen receptors (e.g., BT-20, MDA-MB231) (4,
5).
Equal Expression of erbB2 by Normal and Tumor Cells. The
steady state level of erbB2 in the normal cell strains was not
significantly different from that in the breast tumor cell lines
examined here (Table 1). This contrasts with the observations
of Kraus et al. (7) who reported erbB2 overexpression in the
ZR-75-1 cell line. In the SK-BR-3 tumor cell line, however,
where the gene is amplified approximately 4- to 8-fold, we
detect at least 50-fold higher erbB2 mRNA levels than in the
normal cell strains4 in agreement with Kraus et al. (7).
pS2 mRNA Is Detectable Only in ER-positive Tumor Cell
4 Unpublished results.
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B
EGF Receptor 123 4567
1 2 3
Fig. 1. EGF receptor RNA expression in
normal and tumor breast epithelial cells. A,
Northern blot analysis. Top, \ 0 fig total cellu
lar RNA from 30-50% confluent 172 (Lane
1), 184 (Lane 2), and MCF-7 (Lane 3) cells
were hybridized with an EGF receptor cDNA
probe. The 10.5-kilobase EGF receptor tran
script is indicated, as are the locations of the
28S and 18S rRNA bands detected by UV
fluorescence of the ethidium bromide-stained
RNA after transfer to the filters. Bottom, the
same filter rehybridized with a chicken 0-actin
cDNA probe, which detects a 2.1-kilobaseinR N'A. li. dot blot analysis using serial 2-fold
dilutions (from 5 Mg)of total RNA from nor
mal cell strains 30N (Lane 1), 172 (Lane 2),
and 184 (Lane 3) and established breast tumor
cell lines MCF-7 (Lane 4), ZR-75-1 (Lane 5),
MDA-MB231 (Lane 6), and T47D (Lane 7).
Filters were hybridized with an EGF receptor
cDNA probe (top) and a chicken /3-actin cDNA
probe (bottom). Amounts detected with each
probe are indicated relative to the normal 184
cell strain (=1.0).
EGF Receptor
10.5-,
>28S
>18S
Relative amount 1.1 12 1.0j06 .06 1.2 0.1
Actin
Aeitn
2.1.
1 2 3
Relative amount 12 1j6 UO 15 1.2 1.9 16
Table 1 Expression ofprotooncogenes and growth factors in normal and tumor-derived breast epithelial cells
Northern blots were hybridized with the indicated probes (see Figs. 1 and 2) and specific bands were quantitated by densitometric scanning. Values are expressed
relative to the amounts detected in normal 184 cells (=10) and are the average of results from 3 or more RNA preparations. Data for DFCI-1 medium growth
conditions, given in parentheses, are averages from at least two separate experiments. Equivalent RNA loading was verified by reprobing the blots with ; Â¡u-tinand
rare corrections (less than 2-fold) are reflected in the values given. Standard errors were within 10-20%.
Normal184172TumorER-MDA-MB231Hs578TBT-20ER+MCF-7ZR-75-1T47DEGFR10126640
(30)''<0.5
(0.5)<0.5
(<0.5)<0.5TCPÂ«10149UD3(3)1-2
(2)2(3)2TGF/310149116(5)6(6)8-9UDc-myc1010394(13)2-3(5)3(5)2erbB2Â°10 1105161219(15)10pS2UDCUDUDUDUD
(UD)+
(+)+
(+>UDHa-ro/10918309(7)8(4)1011N-ros101325251590-150''60-100"7
" 4.6-kilobase transcript on Northern blots.
* 1.2-kilobase transcript on Northern blots.
c UD, undetectable.
'' Amplified gene.
Lines. Analysis of the normal and tumor cell lines for expression
of the estrogen-inducible/jS^ gene revealed hybridizable mRNA
in only two cell lines: MCF-7 cells, where its presence was
initially detected (55); and in ZR-75-1 cells. None of the other
established lines, including the ER+ T47D cells, or the normal
epithelial strains produced this mRNA (Fig. 4, pS2 probe).
mRNAs for Transforming Growth Factors a and ÃŸAre Pro
duced by Normal Mammary Epithelial Cell Strains. TGFa me
diates its growth-promoting effects through the EGF receptor
(56). Its production by breast carcinoma cell lines has been
documented (6) and led us to investigate the relative expression
of the gene in normal and tumor cells. In the MDA-MB231
cells (Fig. 4, TGF<* probe, Lane 7; Table 1) mRNA levels were
close to those in the three normal strains (Lanes 1-3), whereas
in Hs578T cells (Lane 8) no TGFa mRNA was detected. Lower
amounts of TGFa mRNA were quantitated in the ER-t- tumor
lines, MCF-7, ZR-75-1, and T47D (Lanes 4-6).
In contrast to the results with TGFa, no significant differ
ences in TGF/3 mRNA expression were observed between the
normal cell strains and most of the tumor lines (Fig. 4, TGF/3
probe; Table 1). The sole exception is the T47D line, which
does not produce detectable amounts of TGF/3 mRNA (Lane
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Fig. 2. Southern analysis of the EGFR gene in normal and tumor breast
epithelial cells. Five ng of DNA from normal 184 (Lane 1) and tumor MCF-7
(Lane 2). BT-20 (Lane 3), and A431 (Lane 4) cells were digested with Â«awl11
and analyzed by Southern blotting as described ("Materials and Methods").
Hybridization with the EGFR cDNA probe is shown. Markers are a "P-labeled
A///;nlllI digest (Lane 5). Arrow, BamHl restriction fragment length polymor
phism at Â«3.9kilobases observed in the 184 strain.
Table 2 EGF binding to 184 normal and MCF-7 tumor cells
Determination of EGF binding to 184 and MCF-7 cells at the indicated final
cell densities was performed by incubation for 2 h at 37"C with '"I-EGF
concentrations of 12.5 ng/ml (Experiment 1) or 7.5 ng/ml (Experiment 2) in thepresence and absence of 10~' M unlabeled EGF. The difference between triplicate
assays for total and nonspecific binding is given.
Experiment Celltype1
184MCF-72
184MCF-7MCF-7MCF-7Cells/35
mm1.6
X10'1.2
x10'5.6
X10*3.4
x10s1.2
x10'1.8
x 10'Specific
'"I-EGF binding
(fmol/106cells)99.72.795.62.42.45.0
6). These results are not surprising in view of reports demon
strating that the regulation of TGF/3 activity is posttranslational
(37, 57).
N-Â«wIs Overproduced by Established Tumor Cell Lines When
Amplified. The N-raj gene is overexpressed in the MCF-7 and
ZR-75-1 lines compared to the normal strains (Fig. 4, N-ros
probe; Table 1). Amplification of the N-ras gene approximately
10-fold in the MCF-7 (Ref. 58 and data not shown) and ZR-
75-1 (data not shown) lines accounts for these increased levels.
20
125IEGF(x101Â°)M
Fig. 3. Analysis of EGF binding in normal 184 cells. Cells were grown to
confluency (1 X 106/35-mm well) and incubated with increasing concentrations
of '"I-EGF (0.05-10 ng/ml) for 2 h at 37'C as described in "Materials and
Methods." Specific binding is the difference (duplicate determinations) between
total '"I-EGF binding in the presence and absence of 10~7 M radioinert EGF.
Inset, Scatchard plot of the data.
In contrast, Ha-roy mRNA levels are nearly identical in the
normal strains and in the tumor lines (Table 1).
Expression of c-myc Is Lower in Tumor Cell Lines than in
Normal Cells. Fig. 4 (myc probe) shows that c-myc steady state
mRNA levels are somewhat higher in the normal strains (Lanes
1-3) than in the tumor lines (Lanes 4-8), and a similar result
is shown quantitatively in Table 1. Thus, contrary to the over-
expression of c-myc that is associated with gene amplification
in biopsy samples (26,28, 29), we have found that c-myc mRNA
levels are generally lower than normal in the tumor lines
examined here.
Effect of Different Growth Media on Gene Expression. In
order to ascertain whether the differential gene expression
observed in the comparisons of normal and tumor cells was due
simply to the different culture media in which the cells were
grown, mRNA levels were examined in cells grown in the low
serum-containing DFCI-1 medium. The MCF-7 cell line can
be successfully cultured in DFCI-1 medium for periods of 1 to
2 weeks at population-doubling times (Â»25h) similar to those
in the standard medium containing 10% PCS (9). The differ
ential expression of EGF receptor, TGFÂ«, and pS2 genes ob
served when MCF-7 cells were cultured in the standard medium
was maintained when these tumor cells were grown for 2-3
population doublings in DFCI-1 medium (Table 1). Thus, con
stituents in the DFCI-1 medium did not alter the expression of
these genes under short-term culture conditions. Similar results
were obtained in comparisons of the growth of the ZR-75-1,
BT-20, and MDA-MB231 lines in DFCI-1 medium (Table 1).
However, growth in DFCI-1 medium increased the amount of
EGF receptor mRNA in the MCF-7 cells to detectable levels
and augmented c-myc expression in BT-20 cells. The compo
nents of DFCI-1 medium responsible for this effect are being
investigated.
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4.5-
1 2345678
28S
12345678
18S {
Fig. 4. Expression of TGFa, TGF0, c-myc,
N-ras, and pS2 in normal and tumor-derived
breast epithelial cells. Thirty /ig total cellular
RNA from normal cell strains 30N (Lane 1),
172 (/.//Â«<â€¢2), 184 (Lane 3), and established
breast tumor cell lines MCF-7 (Lane 4), ZR-
75-1 (Lane 5), T47D (Lane 6), MDA-MB231
(Lane 7), and Hs578T (Lane 8) were analyzed
by Northern blotting with the indicated probes.
Specific band sizes are indicated in the panels
for each of the transcripts analyzed. Some
cross-hybridization to either the 28S or 18S
rRNA was observed for the TGF0 and N-ras
probes, respectively.
c-myc
1 2345678
N-ras
12345678
2.5.1
]â€¢ 28S -[
l
} 18S -[
-1.3
0.6
18S
DISCUSSION
We have compared normal and tumor-derived human breast
epithelial cells for their expression of several genes, whose
altered structure or expression has been associated with the
initiation and/or progression of breast cancer. Although some
studies of gene expression in tumor cell lines have already been
reported (8, 59-61), this is the first in which ER+ and ER-
breast tumor lines have been compared with normal breast
epithelial cells growing in long-term cell culture and under the
same culture conditions.
Normal Cells Synthesize High Levels of the niR.VVs for the
EGF Receptor and TGFa. We have found that the expression
of the mRNA for the EGFR is much lower in the ER+ tumor
cell lines than in ERâ€”tumor cells. This result is consistent with
previous EGF-binding studies which quantitated the number of
EGF receptors in breast tumor cell lines (4, 5). In addition, our
data show that the production of EGFR mRNA and its encoded
protein in normal cells is quantitatively similar to that in ERâ€”
tumor lines. Scatchard analysis of EGF binding in the normal
cells indicated the presence of approximately 6 x IO4receptors/
cell, with a dissociation constant of 1 n.M.This is the lower of
the two affinity forms of the EGF receptor measurable in breast
tumor epithelial cells (4, 5,62). According to the report of Roos
et al. (62), this form is generally observed in cells with high
total receptor number (e.g., MDA-MB231, BT-20); therefore
its predominance in the normal cells may be correlated with
the high total binding in these cells. Since the normal cells
studied here do not have detectable quantities of estrogen
receptors,4 our results suggest that high EGFR expression in
the absence of gene amplification may be more related to ERâ€”
negative status than to tumorigenicity.
The tumor growth factor TGFa is produced by normal (63)
as well as tumor cell populations (64) and acts by binding to
the EGF receptor (56). The normal breast cells analyzed here
produce higher levels of TGFa mRNA than the tumor cell
lines. Activity measurements on some of the same tumor cells
by Dickson et al. (6) correlate well with the relative amounts of
TGFa mRNA detected in our study, with the exception of
estrogen-stimulated MCF-7 cells, where the activity was com
parable to that found in the MDA-MB231 line (6). In agreement
with our results, Peres et al. (8) have recently shown that levels
of TGFa mRNA in the MDA-MB231 cell line are greater than
those detected in the MCF-7, T47D, and ZR-75-1 cells. Our
results that normal breast cells produce higher levels of TGFa
mRNA than most of the tumor lines analyzed, regardless of
ER status suggest that no direct relationship exists between
TGFa production and tumorigenicity. Similar conclusions have
7045
on July 9, 2019. © 1988 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
GROWTH FACTORS AND ONCOGENES IN BREAST EPITHELIAL CELLS
been drawn by Perroteau et al. (65) who quantitated the levels
of immunoreactive TGFa present in breast tissue extracts and
found no significant correlation with the pathological state of
the tissue.
ER+ Tumor Cell Lines Express pS2 but Do Not Overproduce
Ha-ras mRNAs. The estrogen-responsive pS2 gene expression
in cultured cells correlates well with the results from immuno-
cytochemical analyses, which demonstrated pS2 expression in
88% of ER+ breast tumors and failed to detect thepS2 product
in normal breast tissue (23). As predicted from these studies,
we have found that pS2 mRNA is absent in the normal as well
as in the hormone-independent tumor cell lines analyzed but is
very high in two of the estrogen-dependent lines.
Contrary to the indications of De Bortoli et al. (33), who
quantitated 10-fold higher amounts of Ha-ras p21 protein in
breast tumors (70% were ER+) than in normal breast tissue,
we have observed no significant differences in the mRNA levels
produced by normal and ER+ tumor cells in culture. Only
slight increases in Ha-ras expression in the ER- tumor lines
were detected. Our results are consistent with those of Ohuchi
et al. (66), who concluded that enhanced ras expression is
probably not involved in the maintenance of the transformed
phenotype of breast tumor tissues.
Overexpression of EGFR, erbB2, and N-ras Occurs Concom
itant with Gene Amplification in These Tumor Cell Lines. In
creased EGFR gene expression relative to the normal cell
strains was observed only in the BT-20 tumor cell line, in which
the gene copy number is 7-fold amplified. Similarly, overex-
pression of the N-ras gene correlates with its Overexpression in
two of the ER+ tumor lines studied here. However, the signif
icance of N-ras amplification for the tumorigenic progression
of breast cancer has been questioned, since no tumor biopsy
specimens have yet been reported with amplified N-ras se
quences (34, 58).
A role for erbB2 in breast cancer was proposed in view of
studies that correlated erbB2 gene amplification (25) and high
protein levels (27) with a poor clinical prognosis. Expression
of the erbB2/HER-2/neu oncogene is elevated in approximately
30% of breast cancer biopsies (24, 26-28). In cell culture, we
have seen that normal cells express as much erbB2 mRNA as
the tumor cell lines (Table 1), none of which have an amplified
erbB2 gene (7).4 Thus, the tumorigenic phenotype of the cell
lines analyzed here is not dependent upon high erbB2 expres
sion.
This comparison of normal and tumor-derived mammary
epithelial cells grown in culture has revealed no consistent
differences between the EGFR, TGFa, TGF/3, erbBI, and N-
ras mRNA levels of ERâ€”tumorigenic and normal cells except
when the corresponding genes were amplified. In the ER+
tumor lines, however, expression of EGF receptor and TGFa
mRNAs was markedly lower than in the normal cells, and pS2
was expressed. The molecular basis for differences between
ER+ and ERâ€”cells is a fundamental problem in breast cancer
research. This study emphasizes the importance of comparative
studies of normal and tumor cells under similar growth condi
tions for future investigations. Ideally such analyses should be
carried out with primary tumor cells grown in culture. Work
directed toward this goal is in progress in our laboratory.
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